Compare Ascendis Pharma A/S (ASND) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Uber Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Uber Technologies Inc trades at $78.43 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 9.5× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UBER | |
|---|---|---|
Market Cap | $16.78B | $159.38B |
Sector | Health | Industrials |
52-Week High | $277.18 | $100.10 |
52-Week Low | $189.74 | $65.94 |
Enterprise Value | $17.15B | $168.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
Uber (UBER) trades at $78.54, up 4.69% today, reflecting strong bullish momentum. The stock shows robust fundamentals with revenue growth from $44.0B in 2024 to $52.0B in 2025 and a net income margin of 19.32%. Technical indicators are bullish, with the price above key support levels and moving averages signaling upward trend. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Spain and Germany, though cost management is evident through HR layoffs and AI spending caps.
The outlook for Uber is positive, driven by revenue expansion and profitability improvements, but risks include intense competition and regulatory scrutiny. Analyst consensus is strongly bullish with a $102.88 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
